Centre for Heart Research, Westmead Institute for Medical Research, The University of Sydney, Westmead, NSW, 2145, Australia.
Department of Cardiology, Westmead Hospital, Westmead, NSW, 2145, Australia.
Sci Rep. 2019 Jul 22;9(1):10579. doi: 10.1038/s41598-019-47022-w.
We have previously reported a subpopulation of mesenchymal stromal cells (MSCs) within the platelet-derived growth factor receptor-alpha (PDGFRα)/CD90 co-expressing cardiac interstitial and adventitial cell fraction. Here we further characterise PDGFRα/CD90-expressing cardiac MSCs (PDGFRα + cMSCs) and use human telomerase reverse transcriptase (hTERT) over-expression to increase cMSCs ability to repair the heart after induced myocardial infarction. hTERT over-expression in PDGFRα + cardiac MSCs (hTERT + PDGFRα + cMSCs) modulates cell differentiation, proliferation, survival and angiogenesis related genes. In vivo, transplantation of hTERT + PDGFRα + cMSCs in athymic rats significantly increased left ventricular function, reduced scar size, increased angiogenesis and proliferation of both cardiomyocyte and non-myocyte cell fractions four weeks after myocardial infarction. In contrast, transplantation of mutant hTERT + PDGFRα + cMSCs (which generate catalytically-inactive telomerase) failed to replicate this cardiac functional improvement, indicating a telomerase-dependent mechanism. There was no hTERT + PDGFRα + cMSCs engraftment 14 days after transplantation indicating functional improvement occurred by paracrine mechanisms. Mass spectrometry on hTERT + PDGFRα + cMSCs conditioned media showed increased proteins associated with matrix modulation, angiogenesis, cell proliferation/survival/adhesion and innate immunity function. Our study shows that hTERT can activate pro-regenerative signalling within PDGFRα + cMSCs and enhance cardiac repair after myocardial infarction. An increased understanding of hTERT's role in mesenchymal stromal cells from various organs will favourably impact clinical regenerative and anti-cancer therapies.
我们之前曾报道过血小板衍生生长因子受体-α(PDGFRα)/CD90 共表达的心肌间质和心外膜细胞群中的间充质基质细胞(MSCs)亚群。在这里,我们进一步描述了 PDGFRα/CD90 表达的心脏 MSC(PDGFRα+ cMSCs),并利用人端粒酶逆转录酶(hTERT)过表达来提高 cMSCs 在诱导性心肌梗死后修复心脏的能力。hTERT 在 PDGFRα+ 心脏 MSC(hTERT+ PDGFRα+ cMSCs)中的过表达调节细胞分化、增殖、存活和与血管生成相关的基因。在体内,hTERT+ PDGFRα+ cMSCs 在无胸腺大鼠中的移植显著增加了左心室功能,减少了疤痕大小,增加了心肌梗塞后 4 周时心肌细胞和非心肌细胞亚群的血管生成和增殖。相比之下,移植突变型 hTERT+ PDGFRα+ cMSCs(产生无催化活性的端粒酶)未能复制这种心脏功能改善,表明这是一种依赖端粒酶的机制。移植后 14 天没有 hTERT+ PDGFRα+ cMSCs 植入,表明功能改善是通过旁分泌机制发生的。hTERT+ PDGFRα+ cMSCs 条件培养基的质谱分析显示,与基质调节、血管生成、细胞增殖/存活/粘附和固有免疫功能相关的蛋白质增加。我们的研究表明,hTERT 可以激活 PDGFRα+ cMSCs 中的促再生信号,并增强心肌梗死后的心脏修复。增加对来自不同器官的间充质基质细胞中 hTERT 作用的理解将有利于临床再生和抗癌治疗。